Neutrophils make up the largest fraction of white blood cells produced by the bone marrow with 100 billion cells produced daily. This amount might triple in certain conditions such as infection, inflammation, autoimmunity and cancer.

NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps composed of DNA web like structures decorated with highly cytotoxic components including myeloperoxidase, neutrophil elastase and cathepsin G into the extracellular space. Being the human front-line defense mechanism, once overproduced and released into bloodstream, NETs trigger vascular obstruction, thrombosis, hyperinflammation, increasingly known as “immuno-thrombosis” which leads to permanent organ damage to the pulmonary, cardiovascular, renal and nervous systems.

The time lapse video depicts activated neutrophils expelling NETs (rose web-like structures) into the extracellular space. Animation by Reciprocal Space


Clinical Applications

We are developing a robust pipeline of indications that will soon transform the treatment landscape for patients with life-threatening NET–driven diseases.

Our First-In-Man study is designed to assess the safety and efficacy of therapeutic apheresis, with our NucleoCapture device in patients with sepsis and septic shock. Establishment of clinical proof of concept in sepsis and septic shock with subsequent CE Marking will position us for rapid expansion into a series of indications with unmet medical need.

Click each circle to read more in detail


Diagnostic Applications

Our cell-free DNA extraction In Vitro Diagnostic (IVD) microdevice

Liquid biopsy in cancer and prenatal diagnosis enables the discovery of a wide range of information through sequencing of cell-free DNA from a simple blood sample. Efficient cell-free DNA isolation is a critical step predetermining whole liquid biopsy assay sensitivity. Current extraction methods yield modest quantities of cfDNA with significant fragmentation, which adversely effects the diagnostic accuracy of all current liquid biopsy and NIPT methodologies. Santersus is developing a proprietary cell-free DNA extraction In Vitro Diagnostic (IVD) micro-device based on NucleoCapture technology, leveraging the ability of histone H1.3 molecule to bind all types of cell-free DNA with single digit nanomolar DNA binding constants. We believe Santersus cell-free DNA extraction IVD micro- device will significantly improve the sensitivity and diagnostic utility of existing liquid biopsy and NIPT assays. This will open up new diagnostic opportunities in cancer and non-invasive prenatal screening. The global liquid biopsy market was valued at USD 1.244 billion in 2018 and is projected to reach USD 12.062 billion by 2025, growing at a CAGR of 38.3% from 2017 to 2025. The global non-invasive prenatal testing market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5%